Metabolic Markers

Fasting insulin rises years before fasting glucose becomes abnormal. When cells become insulin-resistant, the pancreas responds by producing more insulin to compensate — successfully keeping glucose normal while insulin climbs. This compensated state is invisible on a fasting glucose test but clearly visible on a fasting insulin measurement. At SPOKEmed, a fasting insulin above 8 mIU/L — even with normal glucose — is clinically meaningful and triggers an insulin-resistance-focused protocol. Most standard care panels do not include fasting insulin, which is precisely why insulin resistance goes undetected until glucose rises and a prediabetes or diabetes diagnosis is made.

Beyond the standard CMP and lipid panel, the most clinically valuable additions are: fasting insulin (earlier insulin resistance detection than glucose or A1C), ApoB (cardiovascular particle risk beyond LDL-C), hs-CRP (systemic inflammation level), uric acid (metabolic stress indicator), and a full thyroid panel including free T3, free T4, and antibodies. Together, these markers complete the picture that a standard panel leaves incomplete and routinely surface the clinical drivers that explain why a patient feels poorly despite being told her labs are normal.

During active metabolic treatment — a new weight loss protocol, GLP-1 therapy, or hormone optimization — reassessment at 3 months provides the first meaningful data on response. Once stable, annual comprehensive panels are appropriate for monitoring and early detection of any emerging shifts. SPOKEmed's follow-up schedule — every 3 to 4 weeks during active treatment — allows for early identification of any needed protocol adjustments.